Investigational drug · Phase 3
Livmoniplimab
Also called: ABBV-151
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "Livmoniplimab"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Livmoniplimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Livmoniplimab" as an intervention, largest first.
- Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03821935 · 364 participants · Start Feb 21, 2019 · Primary completion Jun 2027
Drug: Livmoniplimab; Budigalimab · For: Advanced Solid Tumors Cancer
Sites: Springdale, Arkansas; Duarte, California; Irvine, California · 64 sites in all
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06236438 · 167 participants · Start Apr 10, 2024 · Primary completion Oct 2031
Drug: Livmoniplimab; Budigalimab and 5 more · For: Non-Small Cell Lung Cancer
Sites: La Jolla, California; Pembroke Pines, Florida; Winter Haven, Florida · 61 sites in all
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06632951 · 150 participants (planned) · Start Jan 20, 2025 · Primary completion Mar 2027
Drug: Livmoniplimab; Budigalimab and 5 more · For: Urothelial Carcinoma
Sites: Springdale, Arkansas; San Francisco, California; New Haven, Connecticut · 37 sites in all
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05822752 · 130 participants · Start Sep 21, 2023 · Primary completion Nov 2026
Drug: Budigalimab; Livmoniplimab and 2 more · For: Hepatocellular Carcinoma
Sites: Prescott Valley, Arizona; Springdale, Arkansas; Los Angeles, California · 59 sites in all
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06109272 · 89 participants · Start Jan 11, 2024 · Primary completion Jan 2027
Drug: Livmoniplimab; Budigalimab and 4 more · For: Hepatocellular Carcinoma
Sites: Duarte, California; Irvine, California; Orange, California · 37 sites in all
AbbVieAbbVie (ABBV)
NCT06487559 · 3 participants · Start Sep 11, 2024 · Primary completion Sep 18, 2026
Drug: Livmoniplimab; Budigalimab · For: Hepatocellular Carcinoma (HCC)
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A fully human afucosylated anti-GARP antibody PBA-0111 drives anti-tumor immunity through combined ADCC induction and TGF-β1 pathway blockade.
Spee P, Litwin M, Trojanowski D, et al. · Front Immunol 2026
- Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Shimizu T, Powderly J, Abdul Razak A, et al. · Front Oncol 2024
- First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Shimizu T, Powderly J, Abdul Razak A, et al. · Front Oncol 2024
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.